bDMARDs retention rate in the biosimilar era: A real-life monocentric study
Main Authors: | Andrea Becciolini, Federica Lumetti, Eleonora Di Donato, Salvatore Giordano, Daniele Santilli, Flavio Mozzani, Michele Riva, Gianluca Lucchini, Alarico Ariani |
---|---|
Format: | Article |
Language: | English |
Published: |
AVES
2021-04-01
|
Series: | European Journal of Rheumatology |
Online Access: | https://www.eurjrheumatol.org/en/bdmards-retention-rate-in-the-biosimilar-era-a-real-life-monocentric-study-133357 |
Similar Items
-
Imaging in the Assessment of Musculoskeletal Manifestations Associated with Inflammatory Bowel Disease
by: Andrea Becciolini, et al.
Published: (2021-03-01) -
The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
by: Jie Chang, et al.
Published: (2024-01-01) -
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023-05-01) -
Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-01-01) -
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
by: Marie Kostine, et al.
Published: (2022-10-01)